T1	Drug 20 31	Clopidogrel
T2	Condition 0 16	Contraindication
R1	AND Arg1:T2 Arg2:T1	
T3	Condition 33 40	Smoking
T4	Condition 50 57	smokers
T5	Temporal 42 49	current
R2	Has_temporal Arg1:T4 Arg2:T5	
T6	Condition 75 87	quit smoking
T7	Temporal 88 108	less than six months
T8	Condition 111 121	Malignancy
T9	Mood 122 131	diagnosed
T10	Mood 135 154	under investigation
*	OR T9 T10
T11	Scope 122 154	diagnosed or under investigation
R3	AND Arg1:T11 Arg2:T8	
T12	Condition 157 181	Haematological disorders
T13	Condition 183 190	Anaemia
T14	Condition 192 202	malignancy
T15	Condition 204 222	bleeding disorders
*	OR T15 T14 T13
T16	Scope 183 222	Anaemia, malignancy, bleeding disorders
R4	Subsumes Arg1:T12 Arg2:T16	
T17	Person 225 230	Women
T18	Condition 234 257	child-bearing potential
R5	AND Arg1:T18 Arg2:T17	
T19	Drug 266 281	corticosteroids
T20	Drug 288 309	antithrombotic agents
T21	Drug 310 318	warfarin
R6	Subsumes Arg1:T20 Arg2:T21	
*	OR T19 T20
T22	Condition 321 342	Chronic liver disease
T23	Condition 344 353	Cirrhosis
T24	Condition 355 365	malignancy
T25	Value 384 415	more than twice the upper limit
T26	Measurement 419 439	liver function tests
R7	Has_value Arg1:T26 Arg2:T25	
*	OR T23 T24 T26
T27	Scope 344 439	Cirrhosis, malignancy and patients with more than twice the upper limit of liver function tests
R8	Subsumes Arg1:T22 Arg2:T27	
T28	Observation 442 460	Unable to consent.
T29	Drug 475 502	investigational study drugs
T31	Temporal 503 537	within 1 year prior to study entry
R9	Has_temporal Arg1:T29 Arg2:T31	
T30	Temporal 539 547	Previous
T32	Observation 548 575	participation in this study
R10	Has_temporal Arg1:T32 Arg2:T30	
